Pressure Biosciences Inc (PBIO) Financial Statements (2024 and earlier)

Company Profile

Business Address 14 NORFOLK AVENUE
SOUTH EASTON, MA 02375
State of Incorp. MA
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments4132193010381
Cash and cash equivalents4132193010381
Receivables295155131229475207
Inventory, net of allowances, customer advances and progress billings, including:6861,1485936994160
Inventory6861,148593618765858
Other undisclosed inventory, net of allowances, customer advances and progress billings    (549)(672)(698)
Prepaid expense      7
Intangible current assets  404 577663750
Other undisclosed current assets25819315185179163
Total current assets:1,2431,8571,0571,0901,5141,368
Noncurrent Assets
Operating lease, right-of-use asset28239622177
Property, plant and equipment10311616566923
Long-term investments and receivables6460517171720
Long-term investments6460517171720
Intangible assets, net (including goodwill)317404490577663750
Intangible assets, net (excluding goodwill)317404490577663750
Other undisclosed noncurrent assets     136 
Total noncurrent assets:7669751,245726886792
TOTAL ASSETS:2,0102,8322,3031,8162,4002,160
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14,1062,6013,2272,9252,2291,759
Employee-related liabilities118418451457369
Accounts payable637528772816659589
Accrued liabilities13,4691,9562,0381,6581,113801
Deferred revenue58374723
Debt19,46314,0978,6817,8744,85312,908
Deferred revenue and credits263
Due to related parties635 1668215 
Contract with customer, liability21
Other liabilities 7,7576,3312,9501,2331,537
Other undisclosed current liabilities14213365  260
Total current liabilities:34,40424,62518,51813,8538,35116,726
Noncurrent Liabilities
Long-term debt and lease obligation:  263156   
Liabilities, other than long-term debt14241918 57
Deferred revenue and credits57
Deferred revenue241918
Operating lease, liability140263156 
Other undisclosed noncurrent liabilities150150527 174 
Total noncurrent liabilities:2924167031817457
Total liabilities:34,69625,04119,22013,8718,52516,783
Equity
Equity, attributable to parent, including:(32,686)(22,209)(16,918)(12,055)(6,125)(14,623)
Preferred stock1     
Common stock1379142251713
Additional paid in capital69,00664,26150,31344,26139,77730,834
Accumulated deficit(133,826)(118,277)(96,466)(78,942)(65,728)(55,349)
Warrants and rights outstanding  31,71529,19222,59919,8079,879
Other undisclosed equity, attributable to parent31,99611111
Total equity:(32,686)(22,209)(16,918)(12,055)(6,125)(14,623)
TOTAL LIABILITIES AND EQUITY:2,0102,8322,3031,8162,4002,160

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues1,7292,0021,2211,8102,4582,240
Revenue, net2,240
Cost of revenue
(Cost of Goods and Services Sold)
(2,014)(942)(583)(1,197)(1,280)(1,273)
Gross profit:(285)1,0606386131,178967
Operating expenses(4,614)(5,245)(5,224)(7,616)(6,935)(6,888)
Other undisclosed operating income    1,1971,2801,273
Operating loss:(4,898)(4,185)(4,586)(5,806)(4,477)(4,647)
Nonoperating expense(11,178)(15,968)(11,420)(6,073)(5,222)(6,069)
Interest and debt expense(2,331)(130)(11,920)(795)260185
Loss from continuing operations before income taxes:(18,408)(20,284)(27,926)(12,673)(9,439)(10,530)
Income tax benefit    217  
Loss from continuing operations:(18,408)(20,284)(27,926)(12,456)(9,439)(10,530)
Loss before gain (loss) on sale of properties:(20,284)(27,926)(12,456)(9,439)(10,530)
Other undisclosed net income (loss)   10,341(3,412)(14,034) 
Net loss:(18,408)(20,284)(17,585)(15,868)(23,473)(10,530)
Other undisclosed net income (loss) attributable to parent2,3311301,5794,20713,774(185)
Net loss attributable to parent:(16,077)(20,153)(16,006)(11,661)(9,699)(10,716)
Preferred stock dividends and other adjustments(1,727)(1,658)(1,518)(1,554)(679) 
Other undisclosed net loss available to common stockholders, basic (874)(61)(2,653)(13,095) 
Net loss available to common stockholders, diluted:(17,804)(22,685)(17,585)(15,868)(23,473)(10,716)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(18,408)(20,284)(17,585)(15,868)(23,473)(10,530)
Comprehensive loss:(18,408)(20,284)(17,585)(15,868)(23,473)(10,530)
Other undisclosed comprehensive loss, net of tax, attributable to parent      (185)
Comprehensive loss, net of tax, attributable to parent:(18,408)(20,284)(17,585)(15,868)(23,473)(10,716)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: